Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
Femasys Inc. (FEMY)
Company Research
Source: GlobeNewswire
ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products – FemaSeed®, FemVue®, FemCerv®, and FemCath® – are compliant with the new European Union legislation for medical devices. The MDR certification and the four CE Mark product approvals allow Femasys to deliver its innovative solutions for women’s reproductive health within the EU market. “The CE Mark, which follows MDR certification, provides regulatory approval for us to begin marketing four of our products in the European Union. Further, it serves as independent validation of Femasys’ commitment to the highest standards of quality and safety for our custome
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam [Yahoo! Finance]Yahoo! Finance
- Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in AmsterdamGlobeNewswire
- Femasys gains CE Mark approval for women's health products [Yahoo! Finance]Yahoo! Finance
- Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
- Femasys Receives CE Mark Approval for Four of its Women's Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe [Yahoo! Finance]Yahoo! Finance
FEMY
Sec Filings
- 6/20/24 - Form 8-K
- 6/7/24 - Form DEF
- 5/9/24 - Form 10-Q
- FEMY's page on the SEC website